Reprinted: In-Depth Report on the Cutting Edge of Clinical Research on Peritoneal Metastatic Tumors Worldwide, 2021–2026
Peritoneal metastatic cancer (PM) was once regarded as a “terminal stage of cancer,” but rapid advances in diagnostic and therapeutic technologies are now ushering in a transformative turning point in this field. This review provides an in-depth analysis of cutting-edge developments in the treatment of peritoneal metastatic cancer from 2021 to 2026, with a particular focus on the optimization and innovation of the core strategy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). It demonstrates how multidisciplinary team (MDT) approaches are reshaping patient outcomes and how precision diagnostics and minimally invasive techniques are bringing new hope to this refractory malignancy.
2026-04-10
In-Depth Report on the Cutting Edge of Global Clinical Research on Peritoneal Metastatic Tumors, 2021–2026
Peritoneal metastatic cancer (PM) was once regarded as a “terminal stage of cancer,” but rapid advances in diagnostic and therapeutic technologies are now ushering in a transformative turning point in this field. This review provides an in-depth analysis of cutting-edge developments in the treatment of peritoneal metastatic cancer from 2021 to 2026, with a particular focus on the optimization and innovation of the core strategy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). It demonstrates how multidisciplinary team (MDT) approaches are reshaping patient outcomes and how precision diagnostics and minimally invasive techniques are bringing new hope to this refractory malignancy.
Expert Introduction
Key words:
Related News